Celldex Therapeutics, Inc. is 1.5x more valuable than Anbio Biotechnology by market capitalization ($2.30 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NNNN | CLDX |
|---|---|---|
| Market cap | $1.50 B | $2.30 B |
| US-listed rank | #2317 | #1998 |
| Revenue (latest FY) | $8.65M | $1.54M |
| Net income (latest FY) | $6.40M | -$258.76M |
| Net margin | 74.1% | -16748.0% |
| P/E (trailing FY) | 234.2 | - |
| SEC filings | 40 | 1,268 |
Celldex Therapeutics, Inc. is 1.5x more valuable than Anbio Biotechnology by market capitalization ($2.30 B vs $1.50 B).
In their latest fiscal years, Anbio Biotechnology reported $8.65M in revenue while Celldex Therapeutics, Inc. reported $1.54M.
Full pages: Anbio Biotechnology and Celldex Therapeutics, Inc., or browse the full rankings.